World News Insights
1-3 Minute Gist

Browse Articles or use Lyrarc's US patented "Groups" and "Links" for new insights. A Lyrarc Group of Articles on a topic gives insights into particular angles shown in the Group Title. A Lyrarc Link shows more specific insights for 2 articles.

All Topics Articles

LyrArc brings in selected articles from many of the world's top publications.

Articles are selected by experts and you can see the gist of the important articles.

Wyeth Loses Bout in Fight on a Generic

3 Groups   
New York Times - 09.08.2007 Original article ›
Stephanie Saul, Stephanie, Saul
LyrArc Article Gist
Protonix or Pantoprazole Wyeth's third best selling drug with sales of $1.8 billion has patent that expires in July 2010. Now a judge has ruled that Teva Pharmaceutical can introduce its generic version of this drug, Teva had filed a suit challenging the patent's validity and the judge ruled rejecting Wyeth's request to block the generic version from being marketed. Pantoprazole is used to treat severe inflammation of the esophagus from excess acid production.
Read LyrArc gist ›

Wyeth Hit by Generic Competition and Regulatory Setback

3 Groups   
New York Times - 12.25.2007 Original article ›
Bloomberg News, Bloomberg, News
LyrArc Article Gist
Generics from Teva Pharmaceuticals hurt Wyeth as Teva starts a generic for Protonix a heartburn medicine.
Read LyrArc gist ›

Manufactured Goods Lead Surge in Indian Exports

4 Groups   
New York Times - 07.25.2011 Original article ›
Vikas Bajaj, Vikas, Bajaj

Growth pills

1 Groups   
Economist - 09.28.2006 Original article ›
Economist.Com
LyrArc Article Gist
Mergers between smaller and midsized European drug companies, UCB of Belgium and Schwarz Pharma, Nycomed and Altana, Merck and Serono.
Read LyrArc gist ›
Original article 3 minutes, gist 1 minute

European Midsize Drug Makers Become Possible Takeover Targets - WSJ.com

1 Groups   
Wall Street Journal - 09.26.2006 Original article ›
Jeanne Whalen, Jeanne, Whalen

Europe Drug Firms Join Slimming Trend - WSJ.com

1 Groups   
Wall Street Journal - 01.05.2007 Original article ›
Jeanne Whalen, Jeanne, Whalen, Mike Esterl, Mike, Esterl, Tjeerd Wiersma, Tjeerd, Wiersma

2 Drug Makers See Slowdown, With Mixed Outlooks for Year

1 Groups   
New York Times - 07.27.2007 Original article ›
The Associated Press, The, Associated, Press
LyrArc Article Gist
Amgen is seeing slower growth. Worldwide sales of anemia drug Aranesp declined 10% after FDA required stronger warning labels. Aranesp was its best selling drug for 2006 at $4.12 billion sales.
Read LyrArc gist ›

Biotech Stocks, Once Risky, Now Look Safe

1 Groups   
Wall Street Journal - 10.22.2008 Original article ›

Journals Criticize FDA Trials

2 Groups   
Wall Street Journal - 12.30.2009 Original article ›
Jared A. Favole, Jared, A., Favole, Alicia Mundy, Alicia, Mundy

A Prescription for Chinese Health-Care Stocks

1 Groups   
Wall Street Journal - 06.28.2010 Original article ›
Peter Stein, Peter, Stein

No Mug? Drug Makers Cut Out Goodies for Doctors

1 Groups   
New York Times - 12.31.2008 Original article ›
Natasha Singer, Natasha, Singer

U.S. Opens the Door to Chinese Pills

1 Groups   
Wall Street Journal - 10.09.2007 Original article ›
Nicholas Zamiska, Nicholas, Zamiska
LyrArc Article Gist
Chinese pharmaceuticals makers are getting ready to launch generics products in the US market and have obtained FDA approval of an AIDS drug once its patent expires.
Read LyrArc gist ›

When a Drug Maker Creates a New Pill, Uncle Sam Vets Name

1 Groups   
Wall Street Journal - 03.17.2006 Original article ›
Anna Wilde Mathews, Anna, Wilde, Mathews

Amgen Cuts Mark Biotech Squeeze

2 Groups   
Wall Street Journal - 08.16.2007 Original article ›
Marilyn Chase, Marilyn, Chase
LyrArc Article Gist
How the sales of Amgen's best selling drug for anemia Aranesp are falling off and the cuts Amgen is making as a result.
Read LyrArc gist ›

White House visitor logs show lobbying going strong - The Washington Post

15 Groups   
Washington Post - 05.21.2012 Original article ›
T.W. Farnam, T.W., Farnam
LyrArc Article Gist
White House visitors database shows lobbyists have frequent access to the White House. On one January day, Jan. 17, 2012, lobbyists came with the CEO's of their companies to 1600 Pennsylvania Avenue at 9 am for roundtable with President Obama. The CEO's are on the president's Jobs Concil. At 1 pm representatives from the meat industry arrive. And at 4 pm a lobbyist from Goldman Sachs comes for a meeting with Alan Krueger, chairman of the Council of Economic Advisors. Its a fairly routine day.
Read LyrArc gist ›
Original article 8 minutes, gist 1 minute

Cash Gets More Precious at Tesla

1 Links 10 Groups   
WSJ - 08.02.2017 Original article ›
Charley Grant
LyrArc Article Gist
Charley Grant of WSJ warns that Tesla is in for a difficult time ahead as it ramps up its production of Model 3 cars. He says overhead costs should lead to negative margins during the early rollout stage, and only when the production ramps up could this turn positive. Tesla needs $2 billion in the second half of 2017, and is now turning to debt markets for its capital needs. 

Read LyrArc gist ›
Original article 2 minutes, gist 1 minute

FDA Moves Toward Harder Line on Suicide Risks

2 Groups   
Wall Street Journal - 07.01.2005 Original article ›
Anna Wilde Mathews, Anna, Wilde, Mathews, Heather Won Tesoriero, Heather, Won, Tesoriero

Baxter Infusion Pumps Are Target of FDA Probe

2 Groups   
Wall Street Journal - 07.22.2005 Original article ›
Anna Wilde Mathews, Anna, Wilde, Mathews, Thomas M. Burton, Thomas, M., Burton

Regulator Defends Avastin Decision

2 Groups   
Wall Street Journal - 01.07.2011 Original article ›
Alicia Mundy, Alicia, Mundy

Doctors' Spat Exposes FDA Loophole

2 Groups   
Wall Street Journal - 12.23.2009 Original article ›
Alicia Mundy, Alicia, Mundy, Jared A. Favole, Jared, A., Favole

Panel Keeps Avandia on Market

2 Groups   
Wall Street Journal - 07.31.2007 Original article ›
Anna Wilde Mathews, Anna, Wilde, Mathews
LyrArc Article Gist
Avandia may lose additional sales to Actos a competing drug from Takeda Pharmaceutical if the warning label further discourages users of the drug because of heart risks. There is considerable debate within the FDA itself.
Read LyrArc gist ›

FDA Chief Is in Budget Bind

2 Groups   
Wall Street Journal - 02.27.2008 Original article ›
Anna Wilde Mathews, Anna, Wilde, Mathews

More Cost Cuts Sought From Drug Industry

2 Groups   
New York Times - 07.23.2009 Original article ›
Duff Wilson, Duff, Wilson

Big Pharma's Costly Debt Addiction

2 Groups   
Wall Street Journal - 02.09.2009 Original article ›
John Jannarone, John, Jannarone

Cash-Poor Biotech Firms Cut Research, Seek Aid

2 Groups   
Wall Street Journal - 10.29.2008 Original article ›
Jeanne Whalen, Jeanne, Whalen, Ron Winslow, Ron, Winslow

Support LyrArc

We took a different way to help millions around the world build educated informed mindsets that affects and shapes their lives. For a future that is open, global and digital, with everyone having access to high quality information. We believe in the renewal of America, renewal of Europe, the renewal of India, the rest of Asia, Latin America and Africa. The renewal of our supply chains, health, education, infrastructure, as we rebuild our countries after the pandemic. Literacy and knowledge we believe cannot thrive and grow in a world of web bots, web crawlers, or AI. This requires human curiosity, human learning, and human imagination. We take as inspiration the saying- “One has to be free, and as broad as sky. One has to have a mind that is crystal clear, only then can truth shine in it.” Every contribution whether big or small is precious- in this crisis and ahead.

Support Lyrarc from as small as $1




Support LyrArc →


Copyright © 2006 - 2026 Intelilinks LLC
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us